mRNA Vaccines and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Market Overview

The mRNA vaccines and therapeutics market is expected to register a CAGR of 7.2% over the forecast period (2022-2027).

While the sudden outbreak of the COVID-19 pandemic negatively affected most business sectors, the mRNA vaccines and therapeutics market showed significant growth in 2020 and 2021. The market under study continues to flourish with the detection of a new COVID-19 variant. The increase in demand for the development of new vaccines to control the spread of the coronavirus disease has led to the growth of the market under study. Demand for mRNA vaccines and therapeutics has increased during the pandemic because they are designed to trigger an immune response only to the viral spike protein, which is only one component of the viral membrane and allows the virus to invade target cells. According to data from the Centers for Disease Control and Prevention (CDC), updated in January 2022, the use of mRNA vaccines is safe and effective, and the safety of which has been rigorously tested to help with the COVID-19 pandemic. Therefore, COVID-19 has shown a significant positive impact on the market under review.

Growth in research and development (R&D), collaborations and strategic partnerships along with growing demand for new vaccines and therapeutics and increasing chronic and infectious diseases are expected to drive the growth of the studied market. For example, in January 2021 Ribometrix, Inc. and Genentech (a member of the Roche Group) announced an exclusive worldwide license and collaboration agreement to discover, develop and commercialize novel RNA-targeted small molecule therapeutics against multiple targets. As part of this collaboration, Genentech paid Ribometrix USD 25.0 million upfront and received exclusive rights to several pre-defined targets, including an exclusive global license to develop and commercialize the molecules.

In addition, in February 2022, Eli Lilly and Company invested USD 700.0 million to build a facility at the Port of Boston to support its RNA-based research and development activities. Therefore, the increase in research and development activities, collaborations and strategic partnerships of major players is expected to drive the growth of the study market during the forecast period.

However, strict legal requirements and frameworks and high price associated with mRNA-based vaccines and therapeutics is likely to hinder the market growth.

Scope of the Report

As per the scope of the report, mRNA vaccines and therapeutics enable the combination of the desirable immunological properties. These are prepared in laboratories using mammalian cells and are injected into the body of the target to trigger virus-detecting immune sensors and produce viral antigen proteins within the cells. This enhances the body’s immune system by improving B- and T-cell responses. The mRNA vaccines and therapeutics market is segmented by Vaccine Type (self-amplifying mRNA-Based Vaccines and Conventional Non-Amplifying mRNA-Based Vaccines), by Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Others), by Treatment Type (Monoclonal Antibody, Gene Therapy, Cell Therapy, and Others), by End-User (Research Laboratories and Organizations, Hospitals and Clinics and Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Infectious Disease Segment is Expected to Witness Growth Over the Forecast Period

Infectious diseases by application segment are expected to witness significant growth during the forecast period. The increasing prevalence of Ebola, influenza, human immunodeficiency virus (HIV), and other viral infections including Covid-19 act as major driving factors for this segment.

Earlier in 2020, the outbreak of Covid-19 sparked demand for mRNA vaccines and therapeutics. Several major players are actively involved in the research and development of vaccines to combat the Covid-19 infection. Covid-19 has shown a significant positive impact on the infectious diseases segment of applications.

In addition, non-covid-19 mRNA vaccines for HIV, influenza, and other viral infections are currently in development and clinical trials. For example, in April 2022, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), launched a Phase 1 clinical trial to evaluate three experimental messenger RNA (mRNA)-based HIV vaccines. platform. The HVTN 302 study is sponsored by NIAID and conducted by the NIAID-funded HIV Vaccine Trials Network (HVTN) based at the Fred Hutchinson Cancer Research Center in Seattle.

Additionally, in July 2021, Moderna announced that the first participants had been dosed in a Phase 1 and 2 clinical trial of its quadrivalent influenza candidate, mRNA-1010. Approximately 180 healthy adults in the United States participated in the study and were fully enrolled in early September 2021.Therefore, these increasing mRNA vaccine and therapeutics developments and clinical trials for several infectious diseases is anticipated to grow over the forecast period.

To understand key trends, Download Sample Report